These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 26062425

  • 1. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P, Chen D, Bian J, Xia R, Song X, Wen W, Zhang X, Zhu Y.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [Abstract] [Full Text] [Related]

  • 2. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F, Zeng G, Zhou S, He X, Sun N, Zhu X, Hu A.
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [Abstract] [Full Text] [Related]

  • 3. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
    Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B.
    PLoS One; 2012 May; 7(2):e30676. PubMed ID: 22363469
    [Abstract] [Full Text] [Related]

  • 4. Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC.
    Oja AE, Piet B, van der Zwan D, Blaauwgeers H, Mensink M, de Kivit S, Borst J, Nolte MA, van Lier RAW, Stark R, Hombrink P.
    Front Immunol; 2018 May; 9():2654. PubMed ID: 30505306
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
    Su H, Xie H, Dai C, Ren Y, She Y, Xu L, Chen D, Xie D, Zhang L, Jiang G, Chen C.
    Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
    Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F.
    J Immunol; 2015 Apr 01; 194(7):3475-86. PubMed ID: 25725111
    [Abstract] [Full Text] [Related]

  • 9. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W.
    Hepatology; 2012 Oct 01; 56(4):1342-51. PubMed ID: 22505239
    [Abstract] [Full Text] [Related]

  • 10. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.
    Eur J Cancer; 2015 Nov 01; 51(17):2698-707. PubMed ID: 26329973
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.
    Clin Cancer Res; 2019 Aug 01; 25(15):4663-4673. PubMed ID: 31053602
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Expression and distribution of programmed death receptor 1 and T cell immunoglobulin mucin 3 in breast cancer microenvironment and its relationship with clinicopathological features].
    Shen H, Sheng H, Lu JJ, Feng C, Yao M, Pan H, Xu LS, Shen JF, Zheng Y, Zhou YL.
    Zhonghua Yi Xue Za Zhi; 2018 May 08; 98(17):1352-1357. PubMed ID: 29764038
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.
    Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, Vilella R, Frati C, Alfieri R, Ampollini L, Veneziani M, Silini EM, Ardizzoni A, Urbanek K, Aversa F, Quaini F, Tiseo M.
    Clin Cancer Res; 2018 Jan 15; 24(2):407-419. PubMed ID: 29074606
    [Abstract] [Full Text] [Related]

  • 17. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG, Kim G, Kim KH, Park S, Shin S, Yeo D, Shim HS, Yoon HI, Park SY, Ha SJ, Kim HR.
    J Immunother Cancer; 2021 Dec 15; 9(12):. PubMed ID: 34907028
    [Abstract] [Full Text] [Related]

  • 18. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
    Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M.
    Clin Cancer Res; 2004 Aug 01; 10(15):5094-100. PubMed ID: 15297412
    [Abstract] [Full Text] [Related]

  • 19. Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.
    Su Y, Yamazaki S, Morisue R, Suzuki J, Yoshikawa T, Nakatsura T, Tsuboi M, Ochiai A, Ishii G.
    Pathobiology; 2021 Aug 01; 88(3):218-227. PubMed ID: 33321503
    [Abstract] [Full Text] [Related]

  • 20. CD103+CD8+ T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade.
    Wang P, Huang B, Gao Y, Yang J, Liang Z, Zhang N, Fu X, Li L.
    Cell Immunol; 2018 Mar 01; 325():48-55. PubMed ID: 29448979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.